Earnings summaries and quarterly performance for LivaNova.
Executive leadership at LivaNova.
Board of directors at LivaNova.
BS
Brooke Story
Detailed
Director
DZ
Donald Zurbay
Detailed
Director
DS
Dr. Sharon O’Kane
Detailed
Director
FB
Francesco Bianchi
Detailed
Director
JC
J. Christopher Barry
Detailed
Director
PW
Peter Wilver
Detailed
Director
SE
Stacy Enxing Seng
Detailed
Director
SP
Susan Podlogar
Detailed
Director
TS
Todd Schermerhorn
Detailed
Director
WK
William Kozy
Detailed
Chair of the Board
Research analysts who have asked questions during LivaNova earnings calls.
Adam Maeder
Piper Sandler Companies
6 questions for LIVN
Also covers: ABT, AXNX, EW +14 more
DR
David Rescott
Baird
6 questions for LIVN
Also covers: HAE, INSP, IRTC +7 more
Michael Polark
Wolfe Research
5 questions for LIVN
Also covers: BBNX, BSX, DXCM +13 more
DR
David Roman
Goldman Sachs Group Inc.
4 questions for LIVN
Also covers: ABT, BAX, BBNX +21 more
AP
Anthony Petrone
Mizuho Group
3 questions for LIVN
Also covers: ADMA, ALC, AXGN +24 more
FW
Frederick Wise
Stifel
3 questions for LIVN
Also covers: AORT, ATRC, AVNS +13 more
BF
Brett Fishman
KeyBanc Capital Markets Inc.
2 questions for LIVN
Also covers: ITGR, SHC, SOLV
John McAulay
Stifel
2 questions for LIVN
Also covers: AORT, ATRC, PROF
Matthew Miksic
Barclays PLC
2 questions for LIVN
Also covers: ABT, ATEC, BAX +15 more
Michael Matson
Needham & Company
2 questions for LIVN
Also covers: AORT, ATRC, CNMD +22 more
Mike Matson
Needham & Company, LLC
2 questions for LIVN
Also covers: AORT, ATRC, CNMD +19 more
MT
Matthew Taylor
Jefferies
1 question for LIVN
Also covers: ALUR, BDX, BSX +21 more
Matt Miksic
Barclays Investment Bank
1 question for LIVN
Also covers: ABT, ALC, ATEC +17 more
MT
Matt Taylor
Jefferies & Company Inc.
1 question for LIVN
Also covers: ABT, BAX, BDX +16 more
MS
Michael Sarcone
Jefferies
1 question for LIVN
Also covers: ALC, ALGN, AXGN +12 more
Mike Polark
Wolfe Research, LLC
1 question for LIVN
Also covers: BBNX, BSX, DXCM +6 more
RW
Rick Wise
Stifel Financial Corp
1 question for LIVN
Also covers: BDX, BSX, GEHC +9 more
Recent press releases and 8-K filings for LIVN.
LivaNova Reports Strong Full Year 2025 Results and Provides 2026 Guidance
LIVN
Earnings
Guidance Update
New Projects/Investments
- LivaNova reported strong financial performance for full year 2025, achieving double-digit revenue growth, 150 basis points of adjusted operating margin expansion, and a 15% increase in adjusted diluted EPS.
- The company issued 2026 guidance, projecting revenue growth of 6% to 7% on a constant currency basis, adjusted operating income margin between 20% and 21%, and adjusted diluted EPS in the range of $4.15 to $4.25.
- Effective January 1, 2026, Medicare provider reimbursement for VNS Therapy procedures for drug-resistant epilepsy increased significantly, with hospital outpatient payments rising approximately 48% for new patient implants and 47% for end-of-service procedures compared to 2025 rates.
- Strategic advancements include FDA approval for a cloud-based digital health platform in Epilepsy, with a limited market rollout in 2026, and expected PMA approval for the Obstructive Sleep Apnea (OSA) clinical trial device in the first half of 2026.
7 days ago
LivaNova Reports Strong Q4 and Full Year 2025 Results, Provides 2026 Guidance
LIVN
Earnings
Guidance Update
New Projects/Investments
- LivaNova reported strong financial performance for 2025, achieving double-digit revenue growth, meaningful adjusted operating margin expansion, and robust cash generation, marking its fifth consecutive year of double-digit EPS growth and third consecutive year of double-digit organic revenue growth. For Q4 2025, revenue was $361 million and adjusted diluted EPS was $0.86.
- For full year 2026, the company forecasts revenue growth between 6% and 7% on a constant currency basis, an adjusted operating income margin between 20% and 21%, and adjusted diluted EPS in the range of $4.15-$4.25. Adjusted free cash flow is projected to be $160 million-$180 million.
- The company is advancing its long-term strategy by focusing on the obstructive sleep apnea (OSA) market, with a PMA approval for its clinical trial device expected in the first half of 2026 and a commercial launch device in the second half of 2027. LivaNova is also investing in next-generation products for its cardiopulmonary and epilepsy businesses.
- Growth in 2025 was driven by the successful rollout of Essenz, market share gains in cardiopulmonary consumables, strong commercial execution in epilepsy, and pricing strategies, with epilepsy expected to benefit from improved reimbursement and clinical evidence.
- LivaNova anticipates a $400 million SNIA payment in Q3 2026, which is incorporated into its 2026 guidance and represents a $0.06 unfavorable impact to EPS due to lower interest income.
7 days ago
LivaNova Reports Strong Q4 and Full-Year 2025 Results, Issues 2026 Guidance
LIVN
Earnings
Guidance Update
New Projects/Investments
- LivaNova reported strong financial results for Q4 2025, with revenue increasing 9.5% on a constant currency and organic basis to $361 million, and adjusted diluted EPS reaching $0.86. For the full year 2025, the company achieved its fifth consecutive year of double-digit EPS growth and third consecutive year of double-digit organic revenue growth.
- The company provided full-year 2026 guidance, forecasting revenue growth between 6% and 7% on a constant currency basis, an adjusted operating income margin between 20% and 21%, and adjusted diluted EPS in the range of $4.15 to $4.25.
- Key growth drivers include improved Medicare reimbursement for VNS Therapy procedures, effective January 1, 2026, with hospital outpatient payments increasing approximately 48% for new implants and 47% for end-of-service procedures. LivaNova is also investing in Obstructive Sleep Apnea (OSA) with a next-generation device launch planned for H2 2027.
- LivaNova ended 2025 with a strong balance sheet, reporting $636 million in cash and $377 million in total debt, reflecting significant debt reduction through early repayments.
7 days ago
LivaNova Announces Q4 and Full-Year 2025 Results and Provides 2026 Guidance
LIVN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- LivaNova reported strong financial performance for Q4 2025, with net revenue increasing 12.1% year-over-year to $360.9 million, and full-year 2025 net revenue growing 10.7% to $1,388.1 million.
- For full-year 2025, the company achieved $183 million in adjusted free cash flow, a 13% increase, and an adjusted diluted EPS of $3.90.
- The company issued 2026 guidance, forecasting net revenue growth of 6.0% - 7.0% (constant-currency), adjusted operating income margin of 20.0% - 21.0%, and adjusted diluted EPS in the range of $4.15 - $4.25.
- Both key segments demonstrated growth in Q4 2025, with Cardiopulmonary revenue increasing 10% and Neuromodulation revenue also increasing 10% on a constant-currency basis.
7 days ago
LivaNova Exceeds Q4 Expectations and Issues 2026 Guidance
LIVN
Earnings
Guidance Update
New Projects/Investments
- LivaNova beat fourth-quarter expectations in 2025, reporting $360.9 million in revenue and adjusted EPS of $0.86.
- The company provided medium-term guidance for 2026, forecasting constant-currency revenue growth of 6–7% and adjusted EPS of $4.15–$4.25.
- Strategic advancements include the FDA submission of the aura6000 p-HGNS system for obstructive sleep apnea and FDA approval for a cloud-based digital health platform.
- Institutional trading activity showed notable shifts, with 145 investors adding shares and 146 reducing positions, including REDMILE GROUP removing 808,745 shares (-87.3%) and WALLEYE CAPITAL adding 610,693 shares (+1,564.8%).
7 days ago
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results and Issues 2026 Guidance
LIVN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- LivaNova reported fourth-quarter 2025 revenue of $360.9 million, an increase of 12.1% on a reported basis, with adjusted diluted earnings per share of $0.86.
- For the full-year 2025, the company achieved revenue of $1.39 billion, up 10.7% on a reported basis, and adjusted diluted earnings per share of $3.90. The full-year U.S. GAAP diluted loss per share was $4.45, impacted by a $365.6 million SNIA environmental liability expense.
- The company issued full-year 2026 guidance, expecting revenue to grow between 6.0% and 7.0% on a constant-currency basis, and adjusted diluted earnings per share in the range of $4.15 to $4.25. Adjusted free cash flow for 2026 is projected to be between $160 million and $180 million.
- LivaNova also announced increased provider reimbursement for VNS Therapy for Drug-Resistant Epilepsy procedures, effective January 1, 2026, and U.S. Food and Drug Administration approval for its cloud-based digital health platform.
7 days ago
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
LIVN
Earnings
Guidance Update
Product Launch
- LivaNova reported fourth-quarter 2025 revenue of $360.9 million, an increase of 12.1% on a reported basis, and adjusted diluted earnings per share of $0.86.
- For full-year 2025, the company delivered revenue of $1.39 billion, representing 10.7% reported growth, and adjusted diluted earnings per share of $3.90.
- The company issued full-year 2026 guidance, expecting constant-currency revenue growth between 6.0% and 7.0% and adjusted diluted earnings per share in the range of $4.15 to $4.25.
- Key developments include increased provider reimbursement from U.S. Centers for Medicare & Medicaid Services for VNS Therapy for Drug-Resistant Epilepsy procedures, effective January 1, 2026, and U.S. Food and Drug Administration approval for its cloud-based digital health platform.
7 days ago
LivaNova Outlines Strategic Growth Plan and Financial Targets
LIVN
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- LivaNova reported $1.3 billion in revenue in the last 12 months as of September of last year, achieving 10% organic revenue growth and 17% EPS growth over the past 11 quarters.
- The company projects a high single-digit plus revenue CAGR and low double-digit to mid-teens EPS CAGR from 2025 to 2030, with adjusted operating income margin in the high 20s by 2030.
- LivaNova is strategically entering the obstructive sleep apnea (OSA) market, anticipating $200-$400 million in OSA revenue with 80%+ gross margin and 25%+ adjusted operating margin by 2030, and expects the OSA P&L to break even by 2029.
- A significant upside opportunity exists in the difficult-to-treat depression (DTD) market, potentially unlocking a billion-plus dollar market if CMS grants reimbursement, though this is not included in current long-term financial projections.
- Recent positive updates include a nearly 50% increase in Medicare reimbursement for VNS Therapy procedures in the epilepsy business, effective January 1st of this year, and positive clinical data for CORE-VNS and RECOVER study durability in DTD.
Jan 14, 2026, 9:30 PM
LivaNova Details Growth Strategy and Financial Outlook
LIVN
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- LivaNova projects a high single-digit plus revenue CAGR and low double-digit to mid-teens EPS CAGR from 2025 to 2030, expecting to exit with an adjusted operating income margin in the high 20s.
- The company anticipates a 50% increase in Medicare reimbursement for VNS Therapy procedures in its epilepsy business, effective January 1st of this year, which is expected to improve hospital economics and drive procedure penetration.
- LivaNova plans a full commercial launch for its Obstructive Sleep Apnea (OSA) device in H2 2027, targeting $200-$400 million in revenue and over 25% adjusted operating margin by 2030, with the OSA P&L breaking even by 2029.
- A significant upside opportunity exists in difficult-to-treat depression (DTD) with VNS Therapy, pending a CMS reimbursement decision, which is not currently included in the company's long-range financial plan.
Jan 14, 2026, 9:30 PM
LivaNova outlines strategic growth plan and financial projections through 2030
LIVN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- LivaNova reported $1.3 billion in revenue for the last 12 months as of September of last year, achieving 10% organic revenue growth and 17% EPS growth over the past 11 quarters.
- The company is strategically expanding into the obstructive sleep apnea (OSA) market, with a full commercial launch anticipated in the second half of 2027, projecting OSA revenue between $200 million and $400 million and an adjusted operating margin of 25% plus by 2030.
- Recent positive developments include a significant increase of nearly 50% in CMS reimbursement for VNS Therapy procedures in epilepsy, effective January 1st of this year, which is expected to boost procedure volumes and hospital economics.
- LivaNova's long-range plan (2025-2030) forecasts high single-digit plus revenue CAGR, adjusted operating income margin in the high 20s, and a low double-digit to mid-teens EPS CAGR.
Jan 14, 2026, 9:30 PM
Quarterly earnings call transcripts for LivaNova.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more